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Jaboticaba peel powder (JPP) is rich in bioactive compounds, mainly soluble and insoluble polyphenols with great antioxidant
properties. ,e aim of this study is to evaluate the effects of JPP supplementation on the oxidative stress and hepatic damage in a rat
model of type 2 diabetes mellitus (T2DM). Diabetic rats received vehicle or JPP at 2.7 (JPP-I), 5.4 (JPP-II), or 10.8 (JPP-III) g/L in
drinking water during 8 weeks. JPP-III attenuated hyperglycaemia and dyslipidemia increased by 86% the liver content of nonprotein
thiol groups and by 90% the GSH/GSSG ratio by activating glutathione synthesis. Accordingly, JPP supplementation prevented the loss
of activity of the sulfhydryl-dependent enzyme δ-aminolaevulinic acid dehydratase and attenuated hepatic injury assessed by the
reduction of serum aspartate aminotransferase activity and liver hypertrophy. Our results support that JPP supplementation to T2DM
rats decreases hepatic damage most likely by increasing glutathione synthesis and modulating the thiol/disulfide redox balance.
1. Introduction
Diabetes is a major public health problem that affected about
387 million persons worldwide in 2014. ,is figure is expected
to reach 592 million by 2035 [1]. Type 2 diabetes (T2DM) is
characterised by hyperglycaemia and a variable degree of insulin
resistance in tissues, as well as, disturbances in the metabolism
of lipids, protein, and carbohydrates [2]. Chronic hyper-
glycaemia contributes to oxidative stress, which has been hy-
pothesized as a key component in the development of diabetic
macrovascular complications [3] and hepatic damage [4].
Liver is a crucial organ for both lipid and carbohydrate
metabolism [4]. Lipid and protein oxidation as well as the
depletion of endogenous enzymatic and nonenzymatic
Hindawi
Journal of Nutrition and Metabolism
Volume 2018, Article ID 9794629, 13 pages
https://doi.org/10.1155/2018/9794629
antioxidants have been shown to contribute to liver mem-
brane damage in diabetic models [5]. ,e tripeptide glu-
tathione is a major nonenzymatic antioxidant that plays
a key role in the maintenance of hepatic redox balance and
protection against diabetes-induced liver damage [6, 7]. In
addition, the accumulation of free fatty acids (FFA) in
T2DM increases the hepatic production of very low-density
lipoprotein (VLDL) and impairs insulin signalling [8]. Such
events contribute to the nonalcoholic fatty liver disease [4]
and dyslipidemia, which increase the risk of cardiovascular
disease in diabetic patients [9].
Oral hypoglycaemic drugs and insulin are used to treat
T2DM but are not effective against the development of
macrovascular complications and usually cause side effects,
such as hypoglycaemia, weight gain, and gastrointestinal
intolerance [10]. ,us, nutritional strategies to attenuate
diabetic complications would be of great benefit.
Jaboticaba tree (Myrciaria jaboticaba (Vell.) Berg.) is
native from Brazil, belonging to the Myrtaceae family [11].
Jaboticaba fruit is very tasty and can be consumed fresh or as
juice, liqueurs, and jams [11]. It has attracted attention due
to the high content of phenolic compounds, mainly an-
thocyanins and ellagitannins that are mostly found in the
fruit peel [11, 12]. Jaboticaba also contains insoluble phe-
nolic compounds that are covalently bound to cell wall
structural components such as fibre and structural proteins
[13]. ,e consumption of jaboticaba peel powder (JPP) has
been shown to yield antioxidant effects in the liver, kidney,
and plasma of obese rats [14] and improve insulin sensitivity
in a mouse model of obesity [15]. In addition, JPP treatment
has increased fecal triglycerides and attenuated hepatic lipid
oxidation but has not protected against hepatic steatosis in
obese rats [16]. ,e treatment with jaboticaba extract has
been shown to reduce triacylglycerol and cholesterol plasma
levels but not the hepatic lipid peroxidation in a rat model of
type 1 diabetes (T1DM) [17]. T1DM model is characterised
only by hyperglycaemia but does not mimic the insulin
resistance that occurs in T2DM and plays a pivotal role in the
disease complications. T2DM responds for 90% of DM cases
worldwide; however, JPP effects have not been explored in
T2DM models.
,is work was aimed to evaluate the effects of dietary
supplementation with JPP on the dyslipidemia, oxidative
stress, and hepatic damage in a rat model of T2DM.
2. Materials and Methods
2.1. Jaboticaba Peel Powder. Jaboticaba fruits (Myrciaria
jaboticaba Vell Berg) were collected, washed, and manually
peeled in Campinas (São Paulo, Brazil). ,e peels were
frozen at −18°C and then freeze-dried in a Liobras (São
Carlos, São Paulo, Brazil) freeze-dryer to obtain the JPP,
which was stored at −80°C until the experimental protocol.
Moisture, ash, and protein content were determined
according to [18]. Lipid content was determined according
to the Bligh and Dyer method [19]. Total, soluble, and in-
soluble dietary fibre content were determined according to
AOAC [18]. ,e content of nonfibrous carbohydrate was
calculated by subtracting the above percentages from 100%.
,e soluble polyphenols of JPP were extracted as de-
scribed by [20] with some modifications. JPP (1.0 g) was
first extracted with 15mL of a methanol/water/formic acid
(85 :15 : 0.5 v/v) solution, stirred for 30 s in vortex and
submitted to ultrasound for 5min (ULTRA Cleaner 1600,
São Paulo, Brazil; 135W RMS). ,e extract was centrifuged
(2000×g, 10min), and the pellet was exhaustively extracted
as described above. Supernatant fractions were combined
and used to determine total monomeric anthocyanins by the
pH-differential method [21]. Total monomeric anthocyanin
content was calculated using the molecular weight (MW)
and molar absorptivity (ε) of cyanidin-3-glucoside, 449.2
and 26.900, respectively. Results were expressed as cyanidin-
3-glucoside equivalents. Supernatant fractions were also
used to determine soluble polyphenols [22], using a cali-
bration curve of gallic acid, and total soluble proantho-
cyanidins using a calibration curve of catechin [23].
After drying at 30°C, the pellet (0.2 g) was treated with
10mL of butanol/HCl (97.5 : 2.5 v/v) and 0.7 g of FeCl3 at
100°C for 1 h. ,e supernatant obtained was used to de-
termine insoluble polyphenols by measuring the antho-
cyanidin concentration by assessing the sum of absorbances
at 555 and 450 nm and using a calibration curve of a carob
pod tannin concentrate [24].
Carotenoids were exhaustively extracted from the JPP
(0.5 g) with acetone, transferred to petroleum ether/diethyl
ether (1 :1, v/v), and the solvent was evaporated under N2
flux, and the sample was reconstituted in petroleum ether to
assess the total carotenoid concentration using the specific
absorption coefficient (A 1 cm 1%� 2396) of β-carotene [25].
,e composition of soluble polyphenols of the JPP used
in this study was assessed by high-performance liquid
chromatography coupled to photodiode array and mass
spectrometry detectors and comprises 52% anthocyanins
and 48% nonanthocyanin phenolics.
2.2. Animals and Diabetes Induction. Forty male Wistar rats
(eight weeks old, 150–200 g) were supplied by the Central
Animal House of the Federal University of Santa Maria
(UFSM, RS, Brazil). All procedures were approved by
Committee on Care and Use of Experimental Animal
Resources/UFSM (protocol no.: 086/2013). Animals were
housed in standard polypropylene cages (four rats/cage) and
maintained under controlled room temperature (22± 2°C)
and humidity (55± 5%) with 12 :12 h light and dark cycle
with access to feed and water ad libitum.
After a one-week acclimation period, rats were randomly
divided in two dietary regimens with access to 30 g
diet/day/rat and water ad libitum. ,e nondiabetic control
group received a commercial chow diet (Nuvital CR1,
Quimtia, Colombo, Paraná, Brazil), and diabetic groups
were fed a high-fat diet (HFD), containing 74% commercial
chow (Nuvital CR1, Quimtia, Colombo, Paraná, Brazil), 16%
lard, and 10% sucrose (w/w). After 30 days of dietary ma-
nipulation, overnight fasted animals were intraperitoneally
injected with a freshly prepared solution of streptozotocin
(STZ) (1mL/kg b.w., 35mg/kg b.w.) in 0.1M citrate buffer
(pH 4.4) [26] or only 0.1M citrate buffer (1mL/kg b.w.).
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Seven days after STZ administration, glycaemia was mea-
sured, and only rats that had glycaemia higher than
250mg/dL were assigned to the diabetic groups.
Rats were then divided into 5 groups (8 animals/group)
for an 8-week treatment with JPP as detailed in Table 1.
During this period, rats received drinking solutions ad
libitum, control rats continued to receive the commercial
chow diet (30 g/day/rat), and diabetic rats continued to
receive the HFD (30 g/day/rat).
Food and water intake was recorded daily. Body weight
was measured every 3 days. At the end of the experiment,
rats were fasted for 8 h, and then blood was collected from
the caudal vein, and glucose levels were determined with an
automatic analyser donated by Roche® of Brazil (Active,
Boehringer Mannheim, Indianapolis, Indiana, USA). Sub-
sequently, rats were anaesthetised with isofluorane, and the
blood was collected by cardiac puncture into tubes with no
additives. Serum was obtained after blood centrifugation at
2000×g for 15min and was then stored at −20°C until
biochemical analyses.
A liver portion was homogenised in phosphate buffered
saline (PBS) (pH 7.4, 1/8 w/v). Liver homogenate was imme-
diately used to determine thiobarbituric acid reactive substances
(TBARS). A fraction of liver homogenate was centrifuged at
2000×g for 15min to yield a supernatant that was used to
determine the activity of antioxidant enzymes and the contents
of nonprotein thiol groups (NPSH) and protein carbonyl groups.
2.3. SerumBiochemicalAssays. Insulinwasmeasured in serum
by radioimmunoassay using commercial Immunotech kit
(Beckman Coulter Company, Marseille, France). ,e quantita-
tive insulin sensitivity check index (QUICKI) [27] and the fasting
insulin resistance index (FIRI) [28] were calculated as follows:
QUICKI �
1
[log(fasting insulin level) + log(fasting glycaemia)]
,
FIRI �




,e serum levels of total cholesterol (TC), tri-
glycerides (TG), low-density lipoprotein (LDL) and
high-density lipoprotein (HDL) cholesterol, glucose,
and the activities of aspartate aminotransferase (ALT)
and alanine aminotransferase (AST) were determined by
enzymatic methods, using commercial kits (Doles, Goiania,
GO, Brazil). ,e serum level of very-low-density lipo-






,e atherogenic index of plasma (AIP) was calculated





2.4. Markers of Oxidative Stress. Lipid peroxidation in liver
homogenate was estimated colorimetrically by measuring
TBARS [31]. Hepatic protein carbonyl group was determined
by reaction with 2,4-dinitrophenylhydrazine (DNPH) at
240nm [32]. Hepatic NPSH levels were measured as described
in [33] after sample deproteinization with 4% trichloroacetic
acid. ,e levels of reduced glutathione (GSH) and oxidised
glutathione (GSSG) weremeasured by the fluorimetric method
using O-phthalaldehyde [34], and results were expressed as the
GSH/GSSG ratio.
2.5. Antioxidant Enzymes Activities. Superoxide dismutase
(SOD) activity was determined at 480 nm [35]. Catalase
(CAT) activity was measured at 240 nm [36]. ,ioredoxin
reductase-1 (TrxR-1) activity was determined at 412 nm [37].
Glutathione peroxidase (GPx) activity was determined at
340 nm [38]. Glutathione reductase (GR) activity was de-
termined according to [39]. Glutathione S-transferase (GST)
activity was determined at 340 nm [40].
Hepatic δ-aminolaevulinic acid dehydratase (δ-ALA-D)
activity was assayed by measuring the rate of porphobili-
nogen (PBG) formation using Ehrlich’s reagent at 555 nm
after sample incubation for 1 h at 37°C [41].
,e protein content of liver tissue supernatant was
measured using bovine serum albumin as standard [42] and
used to calculate enzyme activities in liver tissue.
Table 1: Treatment of experimental groups.
Groups Diet Injection (i.p.) Drinking solution
Control (nondiabetic) Commercial chow diet Vehicle∗ Vehicle#
Diabetic-vehicle HFD STZ Vehicle#
Diabetic JPP-I HFD STZ 2.7 g JPP/L of vehicle
Diabetic JPP-II HFD STZ 5.4 g JPP/L of vehicle
Diabetic JPP-III HFD STZ 10.8 g JPP/L of vehicle
∗STZ vehicle was 0.1M citrate buffer, pH 4.4. #Water containing 0.5% carboxymethyl cellulose was used as vehicle to stabilize the drinking suspension of JPP.
STZ: streptozotocin; HFD: high-fat diet.
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2.6. Inflammatory Cytokine Level. TNF-α concentration in
serum samples was analysed by ELISA (eBIOSCIENCE®,
San Diego, CA, USA).
2.7. Quantitative Real-Time RT-PCR (qRT-PCR) Analysis.
,e gene expression of enzymes involved in the glutathione
synthesis and apoptosis markers were assessed in liver
samples. ,e RNA extraction was performed using Trizol
reagent following the manufacturer’s instructions (Ludwig-
Biotec, São Paulo, Brazil). ,e RNA extracted was measured
by a ,ermo Scientific NanoDropTM 1000 spectropho-
tometer. To perform reverse transcription, RNA was added
to the samples of RNA (1000 ng/μl) with 0.2 μl of DNAase
(Invitrogen Life Technologies, Carlsbad, CA, USA) at 37°C
for 5minutes followed by heating at 65°C for 10minutes.,e
cDNA was generated with Iscript cDNA and Mix Iscript
(Bio-Rad Laboratories, Hercules, CA, USA). qRT-PCR was
conducted in the Rotor-Gene Q 5plex HRM System (Qiagen
Biotechnology, Germany) with 2x QuantiFast SYBR Green
PCR Master Mix (Qiagen Biotechnology, Germany). qRT-
PCR reactions were run in triplicate, using 1 µM of each
primer, 1000 ng/µL of cDNA, RNAase-free water, and 2x
QuantiFast SYBR® Green PCR Master Mix (Qiagen Bio-
technology, Germany). β-Actin was used as the house-
keeping gene, and its expression level was used as an internal
control. ,e relative gene expression was calculated using
the comparative cytosine-thymine (Ct) method and was
expressed as the fold expression compared to the control.
,e specific primer pairs used are described in Table 2.
2.8. Statistical Analyses. Data were analysed using one-way
analysis of variance (ANOVA) followed by post hoc Dun-
can’s multiple range test or Dunnett’s test (for gene ex-
pression data), when necessary. Data that did not meet the
ANOVA assumptions were submitted to the nonparametric
Kruskal–Wallis analysis, followed by a multiple comparison
test. Results were expressed as the mean± SEM, and dif-
ferences were considered statistically significant when
p< 0.05. Data were analysed using the Statistica® 9.1 soft-
ware system (Statsoft Inc., 2004).
3. Results
JPP contains important phytochemicals such as polyphenols
and carotenoids (Table 3). Among these phytochemicals,
soluble polyphenols are found at the greatest concentration,
being composed mostly by cyanidin-3-glucoside, ellagita-
nins and gallotanins (Table 4). JPP is also a good source of
insoluble polyphenols, as well as carotenoids. Besides, JPP
has considerable amount of total dietary fibre (24.4%), being
9.3% soluble dietary fibre (Table 3).
,e average drinking intake for diabetic rats amounted
to 265mL/day/kg b.w. and did not differ among all diabetic
groups during the treatment (data not shown).
Before treatment with JPP, rats that received high-fat
diet and low doses of STZ to induce T2DM had increased
glycaemia when compared to the control group (Table 5;
p< 0.05). After 8-week treatment, only rats that received the
highest dose of JPP (JPP-III) had lower glycaemia (19%) than
the diabetic-vehicle group. T2DM induction did not alter
fasting serum insulin levels. However, the diabetic JPP-I
group had lower insulin level than the diabetic-vehicle group





subunit (GCLcs) GTGGACACCCGATGCAGTAT TCATCCACCTGGCAACAGTC
Glutathione synthase (GS) GCAGGAACTGAGCAGGGTG GCTTCAGCACAAAGTGGCTAG
β-Actin GCAGGAGTACGATGAGTCCG ACGCAGCTCAGTAACAGTCC




Moisture (%) 17.1± 0.2
Ash (%) 3.3± 1.0
Protein (%) 5.6± 0.0
Lipids (%) 1.3± 0.2
Total dietary fibre (%) 24.4± 1.0
Soluble dietary fibre (%) 9.3± 0.9
Insoluble dietary fibre (%) 15.1± 0.1
Nonfibrous carbohydrates (%) 48.3± 0.4
Phytochemicals
Soluble polyphenols (g gallic acid
equivalents/100 g JPP) 9.67± 0.42
Insoluble polyphenols (g condensed
tannins/100 g JPP) 0.73± 0.15
Carotenoids (mg β-carotene
equivalents/100 g JPP) 1.78± 0.13
Table 4: Composition of soluble polyphenols of freeze-dried ja-
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(Table 5; p< 0.05). T2DM induction increased insulin re-
sistance (FIRI index) and decreased insulin sensitivity
(QUICKI index) when compared to the control group
(Table 5; p< 0.05). JPP treatment reduced to control levels
the insulin resistance and improved insulin sensitivity only
at the lowest dose (JPP-I; Table 5; p< 0.05).
T2DM induction increased the levels of TC, TG, LDL-
cholesterol and VLDL-cholesterol, and the atherogenic
index in comparison to the control group (Figures 1(a)–1(c),
1(f), and 1(e); p< 0.05), whereas the HDL-cholesterol levels
did not differ among groups (Figure 1(d); p> 0.05). JPP
treatment did not affect HDL-cholesterol levels (Figure 1(d))
but reduced the total cholesterol levels in diabetic rats at all
doses tested (Figure 1(a); p< 0.05). In addition, treatment
with JPP-II and JPP-III also reduced TG, LDL-cholesterol,
and VLDL-cholesterol levels (Figures 1(b), 1(c), and 1(e);
p< 0.05) and attenuated the cardiovascular risk (AIP, Fig-
ure 1(f); p< 0.05) to values similar to the control levels but
JPP-I had no effect.
,e diabetic-vehicle group had higher liver weight
(31.7%) and serum levels of the inflammatory marker TNF-α
(54.9%) and ALT activity (125.2%) than the control group
(Figures 2(a)–2(c); p< 0.05), although AST serum activity
did not differ among groups (Figure 2(c), p> 0.05). JPP
treatment at the highest dose (JPP-III) prevented the increase
of liver weight (Figure 2(a)), TNF-α levels (Figure 2(b)), and
ALT activity (Figure 2(c)) in diabetic rats (p< 0.05).
Hepatic gene expression of caspase-3 increased after in-
duction of T2DM when compared to control group, whereas
caspase-9 gene expression decreased with induction of T2DM
(Figures 2(d) and 2(e);p< 0.05). Only JPP-I treatment was able
to prevent the increase in caspase-3 expression (Figure 2(d);
p< 0.05), but no treatment was able to restore caspase-9 gene
expression (Figure 2(e); p> 0.05).
T2DM induction increased hepatic lipid oxidation
assessed by TBARS levels (82.9%) and protein oxidation
assessed by the content of protein carbonyl groups (65.4%)
in comparison to the control group (Figures 3(a) and 3(b);
p< 0.05). JPP treatment did not prevent the increase in lipid
or protein oxidation (Figures 3(a) and 3(b); p> 0.05).
T2DM induction also reduced NPSH levels (49.8%), the
GSH/GSSG ratio (47.0%), and the activity of the sulfhydryl-
containing enzyme δ-ALA-D (26.1%) in liver compared to
the control group (Figures 3(c)–3(e); p< 0.05). After 8 weeks
of JPP treatment, the depletion of NPSH groups in liver was
partially prevented by JPP-I and JPP-II, whereas JPP-III
completely restored NPSH levels (Figure 3(c); p< 0.05). ,e
GSH/GSSG ratio was partially recovered by JPP-II and
completely recovered by JPP-III supplementation (Figure 3(d);
p< 0.05). ALA-D activity was also recovered by JPP treatment
but only at the highest dose (Figure 3(e); p< 0.05).
Additionally, T2DM reduced gene expression of GCLcs
(25.3%) and GS (12.3%), two enzymes involved in GSH
synthesis, in comparison to the control group (Figures 3(f )
and 3(g); p< 0.05). ,e treatment with JPP-II and JPP-III
recovered gene expression of GCLcs up to control level
(Figure 3(f ); p< 0.05). On the other hand, the treatment
with JPP-I and JPP-II increased gene expression of GS
expression above control levels (p< 0.05), but the treatment
with JPP-III failed to do so (Figure 3(g); p< 0.05).
T2DM reduced the activities of hepatic antioxidant
enzymes SOD (31.2%), CAT (48.5%), TrxR-1 (48.2%), GPx
(57.5%), and GST (20.6%) but not GR when compared to the
control group (Table 6, p< 0.05). JPP-III supplementation
decreased GR activity (Table 6, p< 0.05). No JPP doses
restored SOD, CAT, TrxR-1, GPx, or GSTactivities impaired
by T2DM (Table 6, p> 0.05).
4. Discussion
Currently much attention has been focused on the potential
of fruit phytochemicals, especially polyphenols, to prevent
and treat chronic diseases such as T2DM [43]. Extractable
polyphenols and anthocyanins were the main bioactive
compounds found in JPP, and they have been associated to
the improvement of oxidative stress, insulin resistance, and
lipid profile in a rat model of obesity [14, 15, 44].
,e content of JPP’s insoluble polyphenols, which refers
to the polyphenols bound to fibres and protein, was higher
than the amount found in other freeze-dried fruits, as cherry,
white grape, strawberry, and apple with peel [45]. Insoluble
polyphenols can be hydrolysed by gut microbiota yielding
phenolic metabolites that can be absorbed promoting
beneficial health effects [46]. Additionally, the JPP used in
this study had higher content of carotenoids (1.78mg/100 g
JPP) than the jaboticaba fruit of the same species cultivated
in Minas Gerais (Brazil) (0.87mg β-carotene/100 g dry
weight basis) [13].
We have demonstrated that the consumption of JPP for 8
weeks reduced glycaemia, dyslipidemia, and hepatic com-
plications in a rat model of T2DM, providing evidence that
JPP treatment has beneficial protective effects even after
Table 5: Effect of JPP treatment on the glycaemia, insulinemia, insulin sensitivity, and insulin resistance of control and diabetic rats.
Control
Diabetic
Vehicle JPP-I JPP-II JPP-III
Onset glucose (mg/dL) 102.3± 1.5 353.3± 29.9∗ 366.7± 20.6∗ 362.0± 16.7∗ 369.7± 42.2∗
End glucose (mg/dL) 96.7± 1.9 469.0± 15.6∗ 443.3± 20.1∗ 422.5± 15.1∗ 379.5± 36.4∗#
Insulin (mU/L) 5.12± 0.6 7.39± 1.4 3.64± 0.7# 10.10± 2.7 8.45± 2.5
QUICKI 0.71± 0.02 0.46± 0.02∗ 0.53± 0.02∗# 0.44± 0.02∗ 0.49± 0.03∗
FIRI 0.56± 0.05 0.82± 0.09∗ 0.58± 0.06# 0.86± 0.08∗ 0.79± 0.08∗
Glycaemia was assessed before (onset) and after (end) JPP treatment, whereas the other measures were only made after JPP treatment. Data are presented as
means± SEM (n � 8). ∗Different from the control group. #Different from the diabetic-vehicle group (ANOVA followed by Duncan’s test, p< 0.05). QUICKI:
quantitative insulin sensitivity check index; FIRI: fasting insulin resistance index.
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diabetes and insulin resistance are installed. Distinct mech-
anisms seem to underline the protective eects of JPP at the
dierent doses tested. While the highest JPP dose decreased
end glycaemia, the lowest JPP dose decreased insulin levels.
Most protective eects of JPP had a linear dose-response
behaviour and were more evident at the highest dose of JPP,
namely, the decrease of liver hypertrophy and plasma alanine
aminotransferase activity (a marker of liver damage) and the
increase of liver thiol levels (increased NPSH levels,
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Figure 1: Serum levels of total cholesterol (a), triglycerides (b), LDL (c), HDL (d), and VLDL (e) and the atherogenic index (f) of diabetic
rats fed high-fat diet and treated with JPP or vehicle for 8 weeks (means± SEM, n  8). ∗Dierent from the control group (p< 0.05);
#dierent from the diabetic-vehicle group (triglycerides, cholesterol, and VLDL: ANOVA-Duncan’s test and HDL and LDL: Kruskal–Wallis
multiple comparison test p< 0.05); JPP: Jaboticaba peel powder; VLDL: very low-density lipoprotein; LDL: low-density lipoprotein; HDL:
high-density lipoprotein.
































































































































Figure 2: Liver weight (a), serum level of TNF-α (b), serum transaminases activity (c), hepatic expression of caspase-3 (d), and hepatic
expression of caspase-9 (e) in diabetic rats fed high-fat diet and treated with JPP or vehicle for 8 weeks (means± SEM, n  8). ∗Dierent
from the control group. #Dierent from the diabetic-vehicle group (ALT, liver histology: ANOVA-Duncan’s test; liver weight: Krus-
kal–Wallis multiple comparison test; caspase-3 and caspase-9: ANOVA-Dunnett’s test; p< 0.05).e gene expression data were normalized
by β-Actin gene. Mean ± SD were obtained from three independent repetitions. ALT: aspartate aminotransferase; AST: alanine ami-
notransferase; JPP: jaboticaba peel powder; TNF-α: tumour necrosis factor alfa.
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behaviour was observed for the protective eects of JPP
against diabetes-induced dyslipidemia. On the other hand, the
benecial eects of JPP by improving insulin signalling and
decreasing the expression of caspase-3 did not obey a linear
dose-response behaviour as they were observed only at the
lowest dose of JPP. ese eects seem to be better explained
by a hormetic response [47].
Anthocyanins likely contributed to the antidiabetic eect
of JPP as the intake of cyanidin 3-glucoside either puried or
from Queen Garnet plum juice (7.4–7.6mg anthocyanin/kg
b.w./day) has been shown to decrease insulinemia and
improve glucose tolerance in diet-induced metabolic syn-
drome in rats [48]. In the present study, we found similar
results after the intake of JPP-I (daily average intake of
10.3mg anthocyanins/kg b.w.). is lowest dose of JPP
improved insulin signalling as indicated by the increased
insulin sensitivity (QUICKI) and decreased insulin re-
sistance (FIRI). ese eects were caused by the ability of
JPP-I to remarkably reduce serum insulin levels, while
keeping glycaemia levels similar to the vehicle group. e
decrease of insulin levels triggered by JPP disappeared at the
highest JPP doses indicating a U-shaped eect characteristic
of hormetic responses [47]. is biphasic dose response
model has been shown to be better than the linearity and
threshold-response models to explain the behaviour of
various toxic and therapeutic drugs [49] and appears to
explain the eect of JPP on insulin signalling. On the other
hand, the hypoglycaemic eect of JPP exhibits a linear dose-
response behaviour (observed at the highest dose, JPP-III;
daily average intake of 37.5mg anthocyanins/kg b.w.). is
eect may be related to low intestinal glucose absorption
either due to dietary bre or due to the inhibition of digestive
α-amylase and α-glucosidase activities by phenolic com-
pounds as recently reported for jaboticaba extracts [50].
Dyslipidemia can result in cardiovascular complications in
T2DMpatients [9], and the atherogenic index can predict future
cardiovascular disease even before the development of diabetes
(prediabetes) [51]. Accordingly, we found an increased ath-
erogenic index in the diabetic-vehicle group. JPP treatment
improved the lipid prole, mainly by decreasing triglycerides
and LDL levels, which consequently attenuated the atherogenic
index. Soluble dietary bre probably contributed to the lipid-
lowering eect of JPP, because it increases the viscosity of the
intestinal content and limits fat absorption by impeding the
action of bile salts and enzymes or by sequestering bile salts [52].
Accordingly, the hypocholesterolemic and hypotriglyceridemic
TABLE 6: Eect of JPP treatment on the activity of antioxidant enzymes in the liver of control and diabetic rats.
Control
Diabetic
Vehicle JPP-I JPP-II JPP-III
SOD (U/mg ptn) 27.2± 0.7 18.7± 0.7∗ 21.0± 1.3∗ 19.3± 0.9∗ 20.4± 1.7∗
CAT (K/mg ptn) 32.6± 1.8 16.8± 0.9∗ 17.3± 0.9∗ 19.2± 1.0∗ 20.1± 3.3∗
TrxR-1 (nmol DTNB/min/mg ptn) 14.1± 0.6 7.3± 0.7∗ 9.8± 0.9∗ 8.8± 0.9∗ 9.0± 1.1∗
GPx (nmol NADPH/min/mg ptn) 4.0± 0.8 1.7± 0.6∗ 1.1± 0.3∗ 1.1± 0.2∗ 1.9± 0.4∗
GR (nmol NADPH/min/mg ptn) 13.3± 1.1 9.6± 2.4 9.9± 0.7 13.3± 1.6 3.8± 0.7∗#
GST (nmol CDNB/min/mg ptn) 504.1± 13.6 400.3± 28.4∗ 344.5± 16.7∗ 377.7± 22.8∗ 356.3± 44.3∗
Data are presented as means± SEM (n  8); ∗dierent from the control group (CAT, SOD, and TrxR-1: Kruskal–Wallis multiple comparison test and GST,
GPx, and GR: ANOVA-Duncan’s test, p< 0.05); JPP: jaboticaba peel powder; SOD: superoxide dismutase; CAT: catalase; TrxR-1: thioredoxin reductase-1;
GPx: glutathione peroxidase; GR: glutathione reductase; GST: glutathione S-transferase; ptn: protein; DTNB: 5,5′-ditiobis(2-nitrobenzoic acid); NADPH:




























Figure 3: TBARS (a), protein carbonyl (b) and NPSH (c) levels, GSH/GSSG ratio (d), δ-ALA-D activity (e), and gene expression of GCLcs
(f ) and GS (g) in the liver of diabetic rats fed high-fat diet and treated with jaboticaba peel powder or vehicle for 8 weeks (means± SEM,
n  8). ∗Dierent from the control group (p< 0.05). #Dierent from the diabetic-vehicle group (TBARS, protein carbonyl, NPSH,
GSH/GSSG ratio, and δ-ALA-D: ANOVA-Duncan’s test; GCLcs and GS: ANOVA-Dunnett’s test; p< 0.05). e gene expression data were
normalized by β-actin gene expression, and mean± SD were obtained from three independent repetitions. TBARS thiobarbituric acid
reactive substances; NPSHnonprotein thiol group; GSH reduced glutathione; GSSG oxidised glutathione; δ-ALA-D  δ-amino-
laevulinic acid dehydratase; GCLcs glutamate-cysteine ligase, catalytic subunit; GS glutathione synthase.
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effects of riceberry in a rat model of T2DM have been attributed
to the presence of fibre (soluble and insoluble) and not to the
polyphenols [5].
,e consumption of fat diet along with the insulin re-
sistance can further increase circulating FFA, which pro-
motes lipotoxicity by increasing VLDL and triglycerides
synthesis in hepatic tissue. ,us, fat liver accumulation in
nontreated T2DM patients can result in hepatic steatosis or
nonalcoholic fatty liver disease (NAFLD), when fat accu-
mulation is associated with inflammatory process [4]. Ac-
cordingly, the rat model of T2DM exhibited dyslipidemia,
insulin resistance, inflammatory response (TNF-α), and
hepatic damage indicated by increased activity of serum
transaminases and liver hypertrophy and apoptosis (in-
creased gene expression of caspase-3). JPP-III treatment was
able to improve the dyslipidemia, most likely by reducing
lipid accumulation in the liver of T2DM rats, which may be
associated with the decrease of liver weight. JPP-III treat-
ment attenuated hepatic damage as indicated by the reduced
serum ALT activity and liver hypertrophy. ,ese protective
effects of JPP were not associated to the prevention of he-
patic lipid oxidation or apoptosis. Excess glucose promotes
an imbalance between reactive species and antioxidant
defences being responsibly for tissue damage in the T2DM
[52]. Accordingly, we found increased lipid and protein
oxidation with concomitant reduction of enzymatic anti-
oxidant defences (SOD, CAT, TrxR-1, GPx, and GST ac-
tivities) in the liver of diabetic rats. T2DM induction also
depleted nonenzymatic antioxidant defences assessed by the
hepatic content of NPSH and the GSH/GSSG ratio. GSH,
which is the major contributor to the hepatic content of
NPSH, can modulate cell death by regulating the redox state
of specific thiol residues of proteins, such as caspases [54].
,e depletion of NPSH levels and the decrease of
GSH/GSSG ratio in T2DM rats were not associated to an
increase in GST activity, which uses GSH to detoxify xe-
nobiotics. Also the depletion of GSH was not associated to
an increase in GPx activity, which uses GSH to remove
peroxides, or to a decreased GR activity, which reduces
oxidised GSH. GSH depletion could be possibly associated to
a failure in the conversion of the oxidised gluthatione into
GSH by the thioredoxin protein or thioredoxin system [55],
confirmed by the decrease in TrxR-1 activity with T2DM
induction. We observed that the depletion of NPSH and
GSH (GSH/GSSG ratio) content was accompanied by de-
creased activity of δ-ALA-D. ,e sulfhydryl-containing
enzyme δ-ALA-D was inhibited upon oxidation of its
sulfhydryl groups and has been suggested to be a sensor for
oxidative stress [56]. ,us, GSH depletion in diabetic rats
was functionally relevant and indicates an imbalance in the
thiol/disulfide redox state that probably contributed to the
hepatic oxidative stress and tissue damage.
Despite restoring GSH levels (NPSH and GSH/GSSG
ratio) and the activity of δ-ALA-D in diabetic rats, JPP
treatment was not able to decrease the hepatic oxidative
damage in lipids or protein oxidation assessed by protein
carbonylation. ,e improvement of NPSH levels and
GSH/GSSG ratio caused by JPP-III was most likely caused by
increased GSH synthesis due to recovered gene expression of
GCLcs, which is the rate-limiting step in GSH biosynthesis
[54]. Cyanidin-3-glucoside has been shown to increase
hepatic GSH synthesis in a culture of liver human cells
(HepG2) by inducing GCLcs expression via the PKA–CREB
signalling pathway [57].,e decrease in the expression of GS
observed in the present study for the JPP-III group (0.4 times
that of control and vehicle group) will not be expected to
decrease GSH synthesis because the activity of GS, which is
upstream GCL in glutathione synthesis, is normally 2 to 4
times higher than GCL [54]. Accordingly, NPSH levels and
GSH/GSSG ratio were linearly increased with the increase in
JPP dose as observed for the gene expression of GCL.
,e beneficial effect of JPP on δ-ALA-D activity is very
important, since this is the rate-limiting enzyme for the
biosynthesis of heme, the prostetic group of haemoglobin.
We can speculate that the protective effect of JPP occurred
by preventing the oxidation of sulfhydryl groups in the
active site of δ-ALA-D.,is antioxidant mechanism is likely
caused by the increased synthesis of GSH due to the
upregulation of gene expression of GCLcs, the main regu-
latory enzyme for glutathione biosynthesis in liver.
Liver complications were observed in T2DM rats as in-
dicated by the tissue hypertrophy and increased activity of
ALT in the serum, which is a better marker of liver damage
than AST activity that remained unchanged. ALT activity has
been long considered as a specific indicator of hepatic
damage, because it is found at higher concentration in liver
than in other tissues [58]. Lipid and protein oxidation reveals
hepatic oxidative stress in our T2DM model, which has been
shown to alter transport function and membrane perme-
ability in hepatocytes [53] and could contribute to the increase
in serum transaminase [59]. ,e hepatic damage was con-
firmed by the activation of the apoptotic pathway as we
observed an increase in gene expression of caspase-3 in the
diabetic-vehicle group. Caspase-3 was most likely activated by
the extrinsic pathway (caspases 8 and 10) as the gene ex-
pression of caspase 9, which belongs to the intrinsic pathway,
was indeed reduced in diabetic rats. Additionally, a decrease
in the redox status of GSH and thioredoxin protein (Trx) can
induce JNK-dependent apoptosis [61]. ,e oxidation of Trx
triggers signalling for the expression of proapoptotic factors,
such as TNF-α, FasL, and Bak [60]. In addition, apoptosis can
be activated by a caspase-independent pathway when the
GSH levels decline, via activation of the apoptosis inducing
factor (AIF) that causes direct DNA fragmentation [61].
Hyperglycaemia has been shown to increase the intrinsic
apoptosis pathway/mitochondrial through oxidative stress
and Bax protein expression in diabetes models [62]. However,
our T2DM model was characterised by increased dietary fat
content and inflammatory process (elevated TNF-α levels),
which can activate the extrinsic apoptosis. In fact, the acti-
vation of TRL-4 and TNF-α receptors in liver has been shown
to activate the extrinsic apoptosis pathway with activation of
caspase 8 and 10 in a rat model of T1DM [63].
Liver necrosis can occur simultaneously with apoptosis,
and both mechanisms of cell death involve caspase activa-
tion. Necrosis is a mechanism of unregulated cell death,
which involves an exacerbated inflammatory process and the
loss of cellular permeability [64]. ,e rupture of cellular
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membrane releases cytosolic transaminases into serum and
triggers cellular events causing cell swelling. ,e hepatic accu-
mulation of triglycerides togetherwith the activation of cell death
by necrosis can contribute to the hepatic hypertrophy in T2DM
rats. ,us, our T2DMmodel was likely associated to necrosis as
indicated by the release of ALT into serum, the inflammatory
process, and the increased gene expression of caspase-3.
Although JPP treatment at the highest doses (II and III)
was not able to decrease caspase-3 expression, the con-
sumption of JPP at the highest dose promoted an initial
recovery of hepatic damage by attenuating the inflammatory
response and preventing changes in liver weight and serum
ALT activity, which is likely related to the preservation of
hepatocyte cell membrane integrity. On the other hand, only
the lowest dose of JPP was able to decrease gene expression
of caspase-3. ,e decrease of caspase-3 expression in JPP-I
may be explained by the reduction in insulin levels, since
insulin can induce apoptosis by activating caspase-3 via
phosphatidylinositol 3-kinase (PI3-kinase) pathway [65].
Additionally, JPP treatment recovered T2DM dyslipi-
demia in a dose-dependent manner and restored non-
enzymatic antioxidant defences (NPSH and GSH/GSSG
ratio), without changes in the enzymatic antioxidant de-
fences (SOD, CAT, TrxR-1, GPx, and GST activities). ,e
highest dose of JPP was particularly effective for recovering
the sulfhydryl reducing status of liver tissue as it yielded the
greatest increase in NPSH levels, GSH/GSSG ratio, and
prevented δ-ALA-D inhibition. ,us, our data suggest that
the modulation of thiol/disulfide redox state, rather than
modulation of the apoptosis pathway, is the major mech-
anism responsible for the protective effect of JPP against
hepatic damage in T2DM.
Our data indicate that JPP had a relevant protective role by
preserving thiol/disulfide redox balance and protecting sensitive
protein thiols from irreversible oxidation triggered by diabetes-
induced oxidative conditions. During oxidative stress, protein
cysteine residues (Prot-SH) can be oxidised to sulfenic acid
(Prot-SOH), which can react with GSH to form protein mixed
disulfides Prot-SDG (glutathionylation), which in turn can
be reduced back to Prot-SH via glutaredoxin (Grx) or
sulfiredoxin (Srx) [54]. ,is is a mechanism to protect
sensitive protein thiols from irreversible oxidation [54].
In conclusion, the present study showed that JPP
treatment at the highest dose (JPP-III) attenuated hyper-
glycaemia, insulin resistance, hyperlipidemia and hepatic
complications in T2DM model. Hepatic protection was
likely mediated by the increase in GSH synthesis that re-
stored NPSH levels and probably prevented the loss of
activity of sulfhydryl-containing enzymes.
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[58] F. Wróblewski and J. S. Ladue, “Serum glutamic pyruvic
transaminase in cardiac and hepatic disease,” Experimental
Biology and Medicine, vol. 91, no. 4, pp. 569–571, 1956.
[59] Y. Weng, L. Yu, J. Cui et al., “Antihyperglycemic, hypolipi-
demic and antioxidant activities of total saponins extracted
from Aralia taibaiensis in experimental type 2 diabetic rats,”
Journal of Ethnopharmacology, vol. 152, no. 3, pp. 553–560,
2014.
[60] M. L. Circu and T. Y. Aw, “Reactive oxygen species, cellular
redox systems, and apoptosis,” Free Radical Biology and
Medicine, vol. 48, no. 6, pp. 749–762, 2010.
[61] K. Aquilano, S. Baldelli, and M. R. Ciriolo, “Glutathione: new
roles in redox signalling for an old antioxidant,” Frontiers in
Pharmacology, vol. 5, pp. 1–12, 2014.
[62] D. E. Francés, M. T. Ronco, J. A. Monti et al., “Hyperglycemia
induces apoptosis in rat liver through the increase of hydroxyl
radical: new insights into the insulin effect,” Journal of En-
docrinology, vol. 205, no. 2, pp. 187–200, 2010.
[63] P. I. Ingaramo, M. T. Ronco, D. E. A. Francés et al., “Tumor
necrosis factor alpha pathways develops liver apoptosis in type
1 diabetes mellitus,” Molecular Immunology, vol. 48, no. 12-
13, pp. 1397–1407, 2011.
[64] M. E. Guicciardi, H. Malhi, J. L. Mott, and G. J. Gores,
“Apoptosis and necrosis in the liver,” Comprehensive Physi-
ology, vol. 3, pp. 1–59, 2013.
[65] J. P. Godbout, K. A. Cengel, S.-L. Cheng, C. Minshall,
K. W. Kelley, and G. G. Freund, “Insulin activates Caspase-3
by a phosphatidylinositol 3′-kinase-dependent pathway,”
Cellular Signalling, vol. 11, no. 1, pp. 15–23, 1999.
[66] A. Quatrin, “Effect of Jaboticaba (Myrciaria jaboticaba (Vell.)
Berg.) on the oxidative stress and inflammatory response in
type 2 diabetes mellitus in rat model,” M.S. thesis, Federal
University of Santa Maria, Santa Maria, RS, Brazil, 2014.
















































































Submit your manuscripts at
www.hindawi.com
